Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pnemoniae and rare H. influenzae strains.

Abstract: The present invention provides complexing agents of Formula I which contain novel photosensitizers and produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.

Abstract: Coumarin derivatives as substrates for cytochrome P450 enzyme.

Abstract: The present invention is to novel compounds of Formula (I), their pharmaceutical compositions, and to the novel inhibition of Caspases for use in the treatment of apoptosis, and disease states caused by excessive or inappropriate cell death.

Abstract: A pharmaceutical formulation comprises, in combination with a penem of formula (I): in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula:  wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier; a &bgr;-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.

Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against pathogenic bacteria, especially anaerobic pathogens.

Abstract: The present invention is to novel sulfonyl isatin compounds of Formula (I), their pharmaceutical compositions, and the novel inhibition of caspases for use in the treatment of apoptosis, and disease states caused by excessive or inappropriate cell death.

Abstract: A method of treating an atypical upper respiratory pathogenic bacteria comprising administering a gemifloxacin compound is disclosed.

Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against pathogenic bacteria, especially anaerobic pathogens.

Abstract: A process for preparing a compound of formula (1) in which P1 and P2 are protecting groups; comprising a) reaction of a compound of formula (5) wherein P1 is as defined for formula (1); with a Raney-nickel catalyst in a solvent under hydrogen to produce a compound of formula (6) wherein P1 is as defined for formula (1); b) protecting the amino group to produce a compound of formula (7) wherein P1 and P2 are as defined for formula (1); and c) selective reduction of the double bond to produce the compound of formula (1).

Abstract: The present invention relates to compositions, kits, and films formed therefrom which are useful as cosmetic or therapeutic agents, as well as methods of their use. The compositions, kits, and films herein are particularly useful as polishes for mammalian nails. More particularly, the present invention relates to compositions and kits which, when applied to mammalian nails form films exhibiting long wear. When applied to mammalian nails, the present kits and compositions form films exhibiting surface energies from about 32 mN/m to about 43 mN/m and polarities from about 0.19 to about 0.29. The present invention further relates to methods of coating mammalian nails with films exhibiting surface energies from about 32 mN/m to about 43 mN/m and polarities from about 0.19 to about 0.29.

Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria.

Abstract: Pharmaceutical compositions and methods of inhibiting calpain using novel indolecarboxamides are disclosed.

Abstract: A compound of formula wherein R1 is hydrogen, or C1-4 alkyl; R2 is C1-10 alkyl, optionally substituted arylC1-4alkyl, optionally substituted heteroaryl C1-4 alkyl optionally substituted C3-7 cycloalkyl, or R1 and R2 together with the nitrogen to which they are attached from a 3 to 10 membered ring which optionally contains an aditional heteroatom selected from oxygen, nitrogen or sulfur, R3 and R4 are C1-6alkyl, hydrogen, nitro, or halogen and R5 is C1-6alkyl, hydrogen, arylalkyl or heteroarylalkyl. The present invention is to the novel compounds of Formula (I), their pharmaceutical compositions, and to the novel inhibition of Caspases for use in the treatment of apoptosis, and disease states caused by excessive or inappropriate cell death.

Abstract: The present invention relates to kits and films formed from the kits which are useful as cosmetic or therapeutic agents, as well as methods of their use. The films and kits herein are particularly useful as polishes for mammalian nails. More particularly, the present invention relates to kits and films which, when applied to mammalian nails exhibit long wear. When applied to mammalian nails, the present kits provide films exhibiting Peak Adhesive Strengths of greater than about 15 g/mm and exhibiting a Toughness Value of greater than about 1.2 MPa or a Wear Value of greater than about 1000 (MPa).sup.2. The present invention further relates to methods of coating mammalian nails with kits and films formed from the kits which exhibit Peak Adhesive Strengths of greater than about 15 g/mm and exhibit Toughness Values of greater than about 1.2 MPa or Wear Values of greater than about 1000 (MPa).sup.2.

Abstract: The present invention relates to compositions useful as cosmetic or therapeutic agents, as well as methods of their use. The compositions herein are particularly useful as coatings for mammalian nails. More particularly, the present invention relates to compositions which, when applied to mammalian nails exhibit long wear properties including excellent adhesion to the nail.

Abstract: The present invention is for long lasting, physically stable, moisturizing lipstick compositions essentially free of water. Said lipsticks contain lipophilic materials with high levels of moisturizers distributed throughout. Said lipsticks resist separation of the moisturizing material from the body of the lipstick.

Abstract: The present invention relates to compositions useful as cosmetic or therapeutic agents, as well as methods of their use. The compositions herein are particularly useful as coatings for mammalian nails. More particularly, the present invention relates to compositions which, when applied to mammalian nails exhibit long wear properties including excellent adhesion to the nail.

Abstract: The present invention relates to kits and films formed from the kits which are useful as cosmetic or therapeutic agents, as well as methods of their use. The films and kits herein are particularly useful as polishes for mammalian nails. More particularly, the present invention relates to kits and films which, when applied to mammalian nails exhibit long wear, particularly at the tip of the nail. When applied to mammalian nails, the present kits and films exhibit Tip Wear Indices, Total Wear Indices, and/or Jagged Indices of less than about 0.90. The present invention further relates to methods of coating mammalian nails with kits and films which exhibit Tip Wear Indices, Total Wear Indices, and/or Jagged Indices of less than about 0.90.

Abstract: The present invention relates to photostable compositions suitable for providing protection against the harmful effects of ultraviolet radiation. The compositions provide excellent efficiency and broad spectrum UV efficacy while exhibiting improved photostability. Methods of use for these compositions are also disclosed. The present compositions comprise:a) an effective amount of a UVA-absorbing dibenzoylmethane sunscreen active;b) a photostabilizing system consisting essentially of an effective amount of 2-ethylhexyl-p-methoxycinnamate; andc) a suitable carrier;wherein the mole ratio of 2-ethylhexyl-p-methoxycinnamate to the dibenzoylmethane sunscreen active is from about 0.15:1 to about 1:1.